Navigation Links
Genesis Biopharma Issues Letter To Shareholders
Date:5/21/2012

LOS ANGELES, May 21, 2012 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, announces the posting of the following Letter to Shareholders to the Investors section of the Company's website at www.genesis-biopharma.com.  In addition, on May 15, 2012, the Company filed with the U.S. Securities and Exchange Commission its Quarterly Report for the three months ended March 31, 2012 on Form 10-Q.  The Form 10-Q includes unaudited interim consolidated financial statements containing the information highlighted below, as well as additional information regarding the Company.  The Form 10-Q is available at www.sec.gov or www.genesis-biopharma.com

Dear Shareholders:

The past months have been a productive and exciting time for Genesis Biopharma as we worked diligently to advance the clinical development of our targeted cancer immunotherapy, a ready-to-infuse autologous cell therapy ("ACT") utilizing tumor infiltrating lymphocytes ("TILs") for the treatment of patients with Stage IV metastatic melanoma.  ACT is based on a physician-sponsored investigational therapy currently available at the National Cancer Institute ("NCI"), MD Anderson Cancer Center and the H. Lee Moffitt Cancer & Research Institute for this same indication. 

During the fourth quarter of 2011, we were pleased to announce our Patent License Agreement with the National Institutes of Health ("NIH"), under which Genesis Biopharma was granted a non-exclusive worldwide license to 43 patents and patent applications.  These include nine U.S. issued patents, 13 U.S. patent applications, and 21 foreign corresponding patents and patent applications relating to adoptive cell therapy using autologous TILs for the treatment of certain cancers. 

W
'/>"/>

SOURCE Genesis Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
2. ValGenesis Suite 2.5 Certified by SAP as Powered by SAP NetWeaver®
3. Scott Brooks Joins Regenesis Biomedical as Chief Operating Officer
4. ThermoGenesis Announces Approval of AXP® by India Ministry of Health
5. ThermoGenesis Announces Acceptance of AXP® Submission by Regulatory Body in China
6. Genesis Biosciences Announces New Hire and Promotions on Operational and Scientific Staff
7. ThermoGenesis Corp. to Announce Fourth Quarter and Year End Results for Fiscal 2011 on September 12, 2011
8. Genesis Biopharma Signs Cooperative Research and Development Agreement With the National Cancer Institute to Develop Cancer Immunotherapies
9. Genesis Biopharma Names Former Member of the Joint Chiefs of Staff General Merrill McPeak to Board of Directors
10. Genesis Biopharma Names David Voyticky to Board of Directors
11. Genesis Biopharma Director William H. Andrews, Ph.D., Profiled in Popular Science Feature Story
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... SHENZHEN, China , July 22, 2014 /PRNewswire/ ... a subsidiary of BGI, the world,s largest genomics ... new human whole exome sequencing service based on ... includes in-depth bioinformatics analysis and SNP validation, and ... 2014. Complete Genomics, highly regarded ...
(Date:7/22/2014)... CAMBRIDGE, Mass. , July 22, 2014 /PRNewswire/ ... of $650 million from philanthropist Ted Stanley ... disorders and bringing new treatments based on molecular ... the world. The Stanley commitment ... among the largest for scientific research in general ...
(Date:7/22/2014)... PLAINS, New Jersey , 22. Juli 2014 ... für die Life-Sciences-Industrie, hat die Ernennung von Marcus ... bekanntgegeben. Herr Bergler hat die europäischen kommerziellen ... Lösungen unterstützt. Bevor er sich Qforma anschloss, war ... bei Cegedim Customer Information, als Vertriebsteam-Leiter Deutschland bei ...
(Date:7/21/2014)... Lawrence Livermore National Laboratory ... and Las Positas College (LPC) recently established a ... hands-on training for veterans, officials recently announced. , ... Positas is designed to help veterans develop ... careers, and establishes a pipeline of qualified candidates ...
Breaking Biology Technology:BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 2BGI Tech Launches Human Whole Exome Sequencing Service on Complete Genomics' Advanced Platform 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 2$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 3$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 4$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 5$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 6$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 7$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 8$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 9$650 million commitment to Stanley Center at Broad Institute aims to galvanize mental illness research 10Qforma gibt Schaffung des neuen Postens als General Manager in Europa bekannt 2Engineering Program Established for Veterans 2Engineering Program Established for Veterans 3
... MOUNTAIN VIEW, Calif., Feb. 25 Alexza,Pharmaceuticals, ... that it has initiated,its first Phase 3 ... an inhalation product candidate being developed for ... schizophrenia or bipolar disorder. Alexza,believes the novel, ...
... t2cure, a clinical,stage biopharmaceutical company developing novel regenerative ... it has appointed,Dr. Petra Rueck Head of Clinical ... join our company", said Manfred Ruediger,CEO of t2cure. ... be of critical importance to t2cure as we ...
... SAN DIEGO, Feb. 25 Speid & Associates, ... is hosting,a six session Webinar series on diabetes ... and April. Speakers will include former Food and,Drug ... Lipicky, as,well as a distinguished list of other ...
Cached Biology Technology:Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 2Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 3Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 4Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine) 5Stem Cell Company t2cure Appoints Dr Rueck Head of Clinical Operations 2The Diabetes Series 2008: Experts Speak About Developing Diabetes Therapeutics 2
(Date:7/22/2014)... Institute of Standards and Technology (NIST), working with ... technique for analyzing biological cells and tissues based ... technique is an advanced form of the widely ... signals that are 10,000 times stronger than obtained ... than obtained from comparable "coherent Raman" instruments, and ...
(Date:7/22/2014)... commercial diet programs and pills, the Weight Watchers program ... the money. The Jenny Craig regimen generated the greatest ... tested, according to researchers at Duke-National University of Singapore ... the June issue of the journal Obesity , ... per dollar spent as insurance carriers consider coverage for ...
(Date:7/22/2014)... Nancy Buccola, MSN, APRN, PMHCNS-BC, CNE, Assistant Professor ... New Orleans School of Nursing, contributed samples used ... material associated with schizophrenia and also suggesting a ... The study, Biological insights from 108 schizophrenia-associated genetic ... Nature , available at http://www.nature.com/nature/journal/vaop/ncurrent/full/nature13595.html., ...
Breaking Biology News(10 mins):Enhanced NIST instrument enables high-speed chemical imaging of tissues 2Enhanced NIST instrument enables high-speed chemical imaging of tissues 3Study compares cost-effectiveness of weight-loss programs and drugs 2Study compares cost-effectiveness of weight-loss programs and drugs 3LSUHSC contributes to work identifying new DNA regions associated with schizophrenia 2
... of an embryonic stem cell, which has the potential to ... complex interaction of genes, proteins that bind DNA, and molecules ... paper, biologists from MIT and the University of California at ... of stem cells into mature heart cells. The study, the ...
... ultrasound waves, MIT engineers have found a way to ... drug delivery more efficient. This technology could pave the ... to the researchers. "This could be used for ... systemic drugs and proteins such as insulin, as ...
... Alps that are not native to that region? Which ... How big a threat will they become to local ... today by the European Commission,s in-house science service, the ... answering these and other questions related to 16 000 ...
Cached Biology News:Probing matters of the heart 2Probing matters of the heart 3Getting (drugs) under your skin 2Getting (drugs) under your skin 3Environment: Pooling information to combat the threat of alien species in Europe 2Environment: Pooling information to combat the threat of alien species in Europe 3
... T Squareds patented high efficiency dynamic valve ... With the most compact, lightweight package in ... use in portable air and gas applications., ... high efficiency. , Includes DC Motor. ...
...
Alkaline Phosphatase (E. coli C75), 100 units. Removes 5'-phosphates from DNA. Category: Nucleotides & Enzymes & Biochemicals, Modifying Enzymes, Alkaline Phosphatases....
... CyScribe First-Strand cDNA Labeling System - ... 50 reactions. For the generation and ... reagents are packaged together for complete ... protocols can be used for performing ...
Biology Products: